Isis Pharmaceuticals to Present a General Corporate Update at Its 2012 Annual Meeting of Stockholders and Open House

Isis Pharmaceuticals to Present a General Corporate Update at Its 2012 Annual
                    Meeting of Stockholders and Open House

PR Newswire

CARLSBAD, Calif., June 5, 2012

CARLSBAD, Calif., June 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS), the leader in antisense therapeutics, today announced that
management will present a general corporate update in conjunction with its
2012 Annual Meeting of Stockholders and Open House on Thursday, June 7 at 2:10
p.m. Pacific Time in Carlsbad, CA.

The agenda for the meeting is as follows:

  o2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only for
    stockholders of record as of April 9, 2012)
  o2:10 p.m. – 3:00 p.m. Corporate Presentation – Stanley T. Crooke, Isis
    Chairman and Chief Executive Officer
  o3:00 p.m. – 5:00 p.m. Scientific Poster Presentation

A live audio webcast of the presentation will be available on the "Investors &
Media" section of the Company's Web site, www.isispharm.com. A replay of the
presentation will be available on the Isis Web site within 48 hours and will
be archived for a limited time.

To RSVP to attend the meeting, please go to Isis' Home Page at
www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners. Isis'
broad pipeline consists of 25 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, and
cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product,
KYNAMRO, following regulatory approval, which is expected in 2012. Isis'
patents provide strong and extensive protection for its drugs and technology.
Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.